Jan 13, 2023 15:06 JST

Source: Eisai

Eisai Launches Renewed Sustainability Page

TOKYO, Jan 13, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced that it has renewed the Sustainability page of its corporate website and it is now accessible to the public.

 


Sustainability Top Page
www.eisai.com/sustainability/index.html

The Eisai's Corporate Concept is "to give first thought to patients and the people in the daily living domain, and to increase the benefits that health care provides to them". Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. For realizing our corporate concept, it is necessary to implement corporate measures based on a long-term perspective under a well-cultivated governance structure. Therefore, it is extremely important for our company to contribute to the sustainability of society by actively addressing global environmental and social issues.

In order to provide information about our sustainability approach and activities in an easy-to-understand manner, we have enhanced the content, and renewed the key visuals, design and page structure. We have also featured our approach, targets and initiatives for improving access to medicines, which Eisai is focusing on, as well as the areas of environment, society and governance.

Through further efforts in our proactive disclosure of information for sustainability, we will aim to develop and maintain favorable relations with all of our stakeholders.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

Source: Eisai
Sectors: Healthcare & Pharm

Copyright ©2026 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


FDA Accepts LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
January 26 2026 10:37 JST
 
Eisai Listed as a Global 100 Most Sustainable Corporation for the Tenth Time
January 21 2026 15:44 JST
 
Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan
January 13 2026 08:50 JST
 
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China
January 06 2026 09:43 JST
 
Eisai Rated "A", the Highest Rating by CDP in Both Climate Change and Water Security Categories for the Second Consecutive Year
December 11 2025 18:41 JST
 
"LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List
December 09 2025 17:51 JST
 
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI(R) (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at CTAD 2025
December 04 2025 17:36 JST
 
New Data Presented at CTAD 2025 Confirms Pharmacological Effect of LEQEMBI(R) (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF
December 03 2025 17:19 JST
 
Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025
December 02 2025 23:01 JST
 
Eisai Submits New Drug Application for Subcutaneous Formulation of "LEQEMBI(R)" for the Treatment of Early Alzheimer's Disease in Japan
November 28 2025 22:00 JST
 
More Press release >>

Latest Press Release


More Latest Release >>